Clinical Scorecard: Evaluating Treatment Outcomes of Venetoclax Combined with Azacitidine in High-Risk Myelodysplastic Syndromes: A Framework for Understanding Response Depth

At a Glance

Key Highlights

• Venetoclax plus azacitidine shows high rates of complete remission and overall response in HR-MDS.
• Increased response depth does not correlate with improved overall survival.
• Treatment aims differ for patients proceeding to transplantation versus those receiving non-transplant disease control.
• Molecular and cytogenetic factors should inform evaluation but not dictate treatment selection.
• Future studies should align response assessment with treatment intent and long-term outcomes.

Guideline-Based Recommendations

Diagnosis

• Assess molecular and cytogenetic risk factors.

Management

• Consider treatment intent: bridging to transplantation or non-transplant disease control.

Monitoring & Follow-up

• Evaluate early response, count recovery, and tolerability.

Risks

• Monitor for infection risk, treatment interruption, and quality of survival.

Patient & Prescribing Data

Patients with treatment-naïve HR-MDS, including those eligible and ineligible for transplantation.

Venetoclax plus azacitidine may serve as a bridge to transplantation but does not guarantee improved transplantation rates or post-transplant outcomes.

Clinical Best Practices

• Differentiate treatment goals based on transplantation intent.
• Document reasons for not proceeding to transplantation and post-transplant outcomes.
• Stratify patient populations based on clinical characteristics and molecular risk.

Related Resources & Content

• Garcia et al. Phase 1b data
• Phase 3 findings on hypomethylating-agent combinations